Creative Planning
CRSP icon

Creative Planning’s CRISPR Therapeutics CRSP Stock Holding History

Creative Planning’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-3,000
Closed -$77K – 1976
2018
Q3 		$77K Buy
+3,000
New +$157K ﹤0.01% 1827

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Creative Planning's CRSP Position: Q2 2026 in Review

Creative Planning reduced its CRISPR Therapeutics (CRSP) stake by 12% in Q2 2026, selling an estimated $239K and leaving 33,065 shares worth $1.8M. The position accounts for ﹤0.01% of the portfolio, ranked #2177.

Creative Planning first reported a position in CRSP in Q4 2017 and has held it in 33 quarters since. The position peaked at $1.92M in Q3 2025. 523 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Creative Planning held 33,065 shares of CRISPR Therapeutics worth $1.8M as of Q2 2026.
  • Creative Planning sold 4,543 CRISPR Therapeutics shares in Q2 2026, an estimated $239K.
  • CRISPR Therapeutics made up ﹤0.01% of Creative Planning's portfolio in Q2 2026, its #2177 holding.
  • Creative Planning first reported a position in CRISPR Therapeutics in Q4 2017 and has held it in 33 quarters since.
  • Creative Planning's CRISPR Therapeutics position peaked at $1.92M in Q3 2025.
  • 523 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Creative Planning's 13F filing for Q2 2026, filed 13 Aug 2026.